Neoadjuvant therapy for oesophagogastric cancer

F. Lordick, H. J. Stein, C. Peschel, J. R. Siewert

Research output: Contribution to journalReview articlepeer-review

93 Scopus citations


Background: The prognosis after surgery for oesophagogastric cancer remains poor. Methods: This review clarifies current indications for neoadjuvant therapy for oesophageal and gastric cancer. A systematic literature research and evaluation of data from international cancer meetings were carried out. Results: Recently published results of large randomized phase III trials underscore the potential value of neoadjuvant treatment for oesophagogastric cancer. However, it remains uncertain which subgroups of patients should routinely undergo preoperative therapy. Metabolic response evaluation during neoadjuvant treatment is a promising tool for the selection of responding patients. Conclusion: Neoadjuvant chemotherapy is a valid option for locally advanced oesophageal and gastric cancer. In the future, more effective and better tolerated treatment strategies, tailored to the specific tumour characteristics of each individual, should be possible.

Original languageEnglish
Pages (from-to)540-551
Number of pages12
JournalBritish Journal of Surgery
Issue number5
StatePublished - May 2004
Externally publishedYes


Dive into the research topics of 'Neoadjuvant therapy for oesophagogastric cancer'. Together they form a unique fingerprint.

Cite this